Zobrazeno 1 - 10
of 105
pro vyhledávání: '"D. John Betteridge"'
Autor:
Stuart D. Horswell, Lee G.D. Fryer, Claire E. Hutchison, Dlear Zindrou, Helen E. Speedy, Margaret-M. Town, Emma J. Duncan, Rasheeta Sivapackianathan, Hetal N. Patel, Emma L. Jones, Adam Braithwaite, Max P.A. Salm, Claire K.Y. Neuwirth, Elizabeth Potter, Jonathan R. Anderson, Kenneth M. Taylor, Mary Seed, D. John Betteridge, Martin A. Crook, Anthony S. Wierzbicki, James Scott, Rossi P. Naoumova, Carol C. Shoulders
Publikováno v:
Journal of Lipid Research, Vol 54, Iss 12, Pp 3491-3505 (2013)
The purpose of this study was to determine the core biological processes perturbed in the subcutaneous adipose tissue of familial combined hyperlipidemia (FCHL) patients. Annotation of FCHL and control microarray datasets revealed a distinctive FCHL
Externí odkaz:
https://doaj.org/article/099d6a65d00b49c4bdc385821c579ab0
Autor:
Harshal A. Deshmukh, Helen M. Colhoun, Toby Johnson, Paul M. McKeigue, D. John Betteridge, Paul N. Durrington, John H. Fuller, Shona Livingstone, Valentine Charlton-Menys, Andrew Neil, Neil Poulter, Peter Sever, Denis C. Shields, Alice V. Stanton, Aurobindo Chatterjee, Craig Hyde, Roberto A. Calle, David A. DeMicco, Stella Trompet, Iris Postmus, Ian Ford, J. Wouter Jukema, Mark Caulfield, Graham A. Hitman
Publikováno v:
Journal of Lipid Research, Vol 53, Iss 5, Pp 1000-1011 (2012)
We carried out a genome-wide association study (GWAS) of LDL-c response to statin using data from participants in the Collaborative Atorvastatin Diabetes Study (CARDS; n = 1,156), the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT; n = 895), and th
Externí odkaz:
https://doaj.org/article/0e30b62ae4ad49fe9ad70c633f99fac3
Autor:
Christina Reith, Colin Baigent, Lisa Blackwell, Jonathan Emberson, Enti Spata, Kelly Davies, Heather Halls, Lisa Holland, Kate Wilson, Jane Armitage, Charlie Harper, David Preiss, Alistair Roddick, Anthony Keech, John Simes, Rory Collins, Elizabeth Barnes, Jordan Fulcher, William G Herrington, Adrienne Kirby, Borislava Mihaylova, Rachel O'Connell, Pierre Amarenco, Philip Barter, D John Betteridge (deceased), Michael Blazing, Jackie Bosch, Louise Bowman, Eugene Braunwald, Christopher P Cannon, Michael Clearfield, Stuart Cobbe, Helen M Colhoun, Björn Dahlöf, Barry Davis, James de Lemos, John R Downs, Paul N Durrington, Bengt Fellström, Ian Ford, Maria Grazia Franzosi, John Fuller (deceased), Curt Furberg, Robert Glynn, David Gordon, Antonio Gotto Jr, Richard Grimm, Ajay Gupta, C Morton Hawkins, Graham A Hitman, Hallvard Holdaas (deceased), Alan Jardine, J Wouter Jukema, John JP Kastelein, Sharon Kean, John Kjekshus, Genell Knatterud (deceased), Robert H Knopp (deceased), Wolfgang Koenig, Michael Koren, Vera Krane, Martin Landray, John LaRosa, Roberto Latini, Eva Lonn, Donata Lucci, Jean MacFadyen, Peter Macfarlane, Stephen MacMahon, Aldo Maggioni, Roberto Marchioli, Ian Marschner, Lemuel Moyé, Sabina Murphy, Andrew Neil, Enrico B Nicolis, Chris Packard, Sarah Parish, Terje R Pedersen, Richard Peto, Marc Pfeffer, Neil Poulter, Sara Pressel, Jeffrey Probstfield, Mahboob Rahman, Paul M Ridker, Michele Robertson, Frank Sacks, Naveed Sattar, Roland Schmieder, Patrick W Serruys, Peter Sever, John Shaw (deceased), James Shepherd (deceased), Lara Simpson, Peter Sleight (deceased), Luigi Tavazzi, Gianni Tognoni, Andrew Tonkin, Stella Trompet, Christoph Wanner, Hans Wedel, Stephen Weis, K Michael Welch, Harvey White, John Wikstrand, Lars Wilhelmsen, Stephen Wiviott, Robin Young, Salim Yusuf, Faiez Zannad, Hiroyuki Arashi, Robert Byington, Robert Clarke, Marcus Flather, Uri Goldbourt, Shinya Goto, Jemma Hopewell, Kees Hovingh, Patricia Kearney, George Kitas, Connie Newman, Marc S Sabatine, Greg Schwartz, Liam Smeeth, Jonathan Tobert, John Varigos, Junichi Yamaguchi
Publikováno v:
The Lancet, 400(10355), 832-845. Elsevier Limited
Background: Statin therapy is effective for the prevention of atherosclerotic cardiovascular disease and is widely prescribed, but there are persisting concerns that statin therapy might frequently cause muscle pain or weakness. We aimed to address t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4616cab962081ebdd901d4a6e1652a20
https://pure.amc.nl/en/publications/effect-of-statin-therapy-on-muscle-symptoms(c31d56e2-803e-4f3b-881a-6f09bfa1f0f4).html
https://pure.amc.nl/en/publications/effect-of-statin-therapy-on-muscle-symptoms(c31d56e2-803e-4f3b-881a-6f09bfa1f0f4).html
Publikováno v:
PLoS ONE, Vol 10, Iss 9, p e0137330 (2015)
The receptor for advanced glycation end products (RAGE) is involved in the pathogenesis of diabetic complications, and soluble forms of the receptor (sRAGE) can counteract the detrimental action of the full-length receptor by acting as decoy. Soluble
Externí odkaz:
https://doaj.org/article/8283e0e727c348239918e275033dc92c
Autor:
D John Betteridge
With the increasing incidence of Type 2 diabetes in the adult population and the realization that this is a vascular disease and a major coronary risk factor, Professor Betteridge has chosen fifty diabetologists to contribute a case which has had an
Autor:
D. John Betteridge, Rafael Carmena
Publikováno v:
Current Atherosclerosis Reports. 21
Purpose of review Observational studies and meta-analyses of randomized clinical trials data have revealed a 10-12% increased risk of new-onset diabetes (NOD) associated with statin therapy; the risk is increased with intensive treatment regimens and
Autor:
Rafael Carmena, D. John Betteridge
Publikováno v:
Nature Reviews Endocrinology. 12:99-110
Treatment with statins has transformed primary and secondary prevention of cardiovascular disease (CVD), including thrombotic stroke. Evidence-based data demonstrate the benefits and safety of statin therapy and help to guide clinicians in the manage
Autor:
Tahira Akbar, Helen M. Colhoun, D. John Betteridge, Shona Livingstone, Graham A. Hitman, John H. Fuller, H. Andrew W. Neil, Paul N. Durrington, Helen C. Looker
Publikováno v:
Diabetologia
Livingstone, S J, Looker, H C, Akbar, T, Betteridge, D J, Durrington, P N, Hitman, G A, Neil, H A W, Fuller, J H & Colhoun, H M 2016, ' Effect of atorvastatin on glycaemia progression in patients with diabetes : an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS) ', Diabetologia, vol. 59, no. 2, pp. 299-306 . https://doi.org/10.1007/s00125-015-3802-6
Livingstone, S J, Looker, H C, Akbar, T, Betteridge, D J, Durrington, P N, Hitman, G A, Neil, H A W, Fuller, J H & Colhoun, H M 2016, ' Effect of atorvastatin on glycaemia progression in patients with diabetes : an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS) ', Diabetologia, vol. 59, no. 2, pp. 299-306 . https://doi.org/10.1007/s00125-015-3802-6
Aims/hypothesis In an individual-level analysis we examined the effect of atorvastatin on glycaemia progression in type 2 diabetes and whether glycaemia effects reduce the prevention of cardiovascular disease (CVD) with atorvastatin. Methods The stud
Autor:
Helen C. Looker, Shona Livingstone, Felix Agakov, D. John Betteridge, Marco Colombo, Helen M. Colhoun, M. Julia Brosnan, Bassam Farran, Paul M. McKeigue, Paul Welsh, Naveed Sattar, Paul N. Durrington
Publikováno v:
Colombo, M, Looker, H C, Farran, B, Agakov, F, Brosnan, M J, Welsh, P, Sattar, N, Livingstone, S, Durrington, P N, Betteridge, D J, McKeigue, P M & Colhoun, H M 2018, ' Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide as independent predictors for cardiovascular disease in type 2 diabetes ', Atherosclerosis, vol. 274, pp. 182-190 . https://doi.org/10.1016/j.atherosclerosis.2018.05.014
Colombo, M, Looker, H C, Farran, B, Agakov, F, Brosnan, M J, Welsh, P, Sattar, N, Livingstone, S, Durrington, P N, Betteridge, D J, Mckeigue, P M & Colhoun, H M 2018, ' Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide as independent predictors for cardiovascular disease in type 2 diabetes ', Atherosclerosis, vol. 274, pp. 182-190 . https://doi.org/10.1016/j.atherosclerosis.2018.05.014
Colombo, M, Looker, H C, Farran, B, Agakov, F, Brosnan, M J, Welsh, P, Sattar, N, Livingstone, S, Durrington, P N, Betteridge, D J, Mckeigue, P M & Colhoun, H M 2018, ' Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide as independent predictors for cardiovascular disease in type 2 diabetes ', Atherosclerosis, vol. 274, pp. 182-190 . https://doi.org/10.1016/j.atherosclerosis.2018.05.014
Background and aimsDeveloping sparse panels of biomarkers for cardiovascular disease in type 2 diabetes would enable risk stratification for clinical decision making and selection into clinical trials. We examined the individual and joint performance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e94c79db8753a26a5a705222df56665f
https://eprints.gla.ac.uk/163114/1/163114.pdf
https://eprints.gla.ac.uk/163114/1/163114.pdf
Autor:
Paul N. Durrington, D. John Betteridge, H. Andrew W. Neil, Coen D.A. Stehouwer, Casper G. Schalkwijk, Helen M. Colhoun, David A. DeMicco, Graham A. Hitman, Valentine Charlton-Menys, Shona J. Livingstone, Gregory M. Preston, Weihang Bao, Sabita S. Soedamah-Muthu, John H. Fuller
Publikováno v:
Diabetologia 58 (2015) 7
Diabetologia, 58(7), 1494-1502. Springer, Cham
Diabetologia, 58(7), 1494-1502
Diabetologia
Diabetologia, 58(7), 1494-1502. Springer, Cham
Diabetologia, 58(7), 1494-1502
Diabetologia
Aims/hypothesis We investigated whether atorvastatin 10 mg daily lowered C-reactive protein (CRP) and whether the effects of atorvastatin on cardiovascular disease (CVD) varied by achieved levels of CRP and LDL-cholesterol. Methods CRP levels were me